tiprankstipranks
Trending News
More News >

DiaSorin S.p.A. Receives Buy Rating from Dylan Van Haaften Due to Strong Market Position and Financial Performance

DiaSorin S.p.A. Receives Buy Rating from Dylan Van Haaften Due to Strong Market Position and Financial Performance

Stifel Nicolaus analyst Dylan Van Haaften maintained a Buy rating on DiaSorin S.p.A. (0GZXResearch Report) today and set a price target of €115.00.

Confident Investing Starts Here:

Dylan Van Haaften has given his Buy rating due to a combination of factors that highlight DiaSorin S.p.A.’s strong market position and financial performance. The company reported slightly better-than-expected results for the fourth quarter, surpassing consensus estimates in both revenue and EBITDA. This solid start to the year is supported by a reiterated guidance of approximately 8% growth excluding COVID-related impacts and robust EBITDA margins of around 34%, indicating a conservative yet promising outlook.
Key growth drivers include the Immuno and LTG segments, with particularly strong performance in the U.S. market, which grew by 15%. Despite some challenges in the European market, which saw a slower growth rate, the overall revenue and strategic positioning remain strong. Additionally, the company’s ability to manage tariff impacts and foreign exchange fluctuations effectively contributes to a positive outlook, making the stock a compelling buy for investors.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue